Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aptevo Therapeutics Inc. (APVO : NSDQ)

• Company Description    Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington. Number of Employees: 36

• Price / Volume Information    Yesterday's Closing Price: $4.95 Daily Weekly Monthly 20 Day Moving Average: 40,947 shares Shares Outstanding: 1.25 (millions) Market Capitalization: $6.17 (millions) Beta: 1.64 52 Week High: $110.88 52 Week Low: $3.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.33% -3.62% 12 Week -32.65% -37.74% Year To Date -47.51% -50.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2401 4TH AVENUE SUITE 1050 - SEATTLE,WA 98121 USA ph: 206-838-0500 fax: 206-838-0503 ir@apvo.com http://www.aptevotherapeutics.com

• General Corporate Information    Officers Marvin L. White - President; Chief Executive Officer John E. Niederhuber - Chairman of the Board of Directors Daphne Taylor - Senior Vice President and Chief Financial Officer Barbara Lopez Kunz - Director Zsolt Harsanyi - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03835L702 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 1.25 Most Recent Split Date: 12.00 (0.06:1) Beta: 1.64 Market Capitalization: $6.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-6.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-24.13 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.53 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 99.59% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -198.50 12/31/25 - -260.82 09/30/25 - -389.34 ROA 03/31/26 - -117.06 12/31/25 - -132.90 09/30/25 - -159.11 Current Ratio 03/31/26 - 3.36 12/31/25 - 3.82 09/30/25 - 4.03 Quick Ratio 03/31/26 - 3.36 12/31/25 - 3.82 09/30/25 - 4.03 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 9.32 12/31/25 - 17.42 09/30/25 - 22.65 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©